Understanding bladder cancer death: Tumor biology versus physician practice

Cancer

Volumn 115, Issue 5, 2009, Pages 1011-1020

  Morris, David S ^b   Weizer, Alon Z ^b   Ye, Zaojun ^b   Dunn, Rodney L ^b   Montie, James E ^b   Hollenbeck, Brent K ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Bladder cancer; End Results Medicare; Epidemiology; Mortality; Practice pattern; Surveillance

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER MORTALITY; CANCER SURGERY; CYSTECTOMY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THERAPY DELAY;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTINEOPLASTIC AGENTS; CYSTECTOMY; FEMALE; HUMANS; MALE; MEDICARE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; RISK ASSESSMENT; SEER PROGRAM; TIME FACTORS; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 61449101686     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24136     Document Type: Article

References (28)

1. Green FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag; 2002.
2. Montie JE, Abrahams NA, Bahnson RR, et al. Bladder cancer. Clinical guidelines in oncology. J Natl Compr Cancer Netw. 2006;4:984-1014.
3. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder ameer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007; 178:2314-2330.
4. Smith JA Jr, Labasky RP, Cockett AT, Fracchia JA, Montie JF., Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, Tl and TIS). The American Urological Association. J Urol. 1999;162:1697-1701.
5. Konety BR, Joslyn SA. Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol. 2003;170:1765-1771.
6. Bianco FJ Jr, Justa D, Grignon DJ, Sakr WA, Pontes JE, Wood DP Jr. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol. 2004;22:290-294.
7. Brice M, Marshall V, Green J, Whitmore WF Jr. Simple total cystectomy for carcinoma of the urinary bladder; 156 consecutive cases 5 years later. Cancer. 1956;9:576-584.
8. Chang SS, Hassan JM, Cookson MS, Wells N, Smith JA Jr. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol. 2003; 170:1085-1087.
9. Fahmy NM, Mahmud S, Aprikian AG. Delay in the surgical treatment of bladder cancer and survival: systematic review of the literature. Eur Urol. 2006;50:1176-1182.
10. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol. 2001;166:1296-1299.
11. Lee CT, Madii R, Daignault S, et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol. 2006;175:1262-1267.
12. Raj GV, Herr H, Serio AM, et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol. 2007;177:1283-1286.
13. Miller DC, Taub DA, Dunn RL, Montie JE, Wei JT. The impact of comorbid disease on cancer control and survival following radical cystectomy. J Urol. 2003;169:105-109.
14. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol. 2006; 24:5552-5564.
15. Holmang S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol. 1995;153:1823-1826.
16. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666-675.
17. Warren JL, Kiabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 suppl):IV3-IV18.
18. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Program Populations (1969-2004). Bethesda, Md: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008.
19. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8-27.
20. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
21. Kiemeney LA, Witjes JA, Verbeek AL, Heijbroek RP, Debruyne FM. The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group. Br J Cancer. 1993;67:806-812.
22. May M, Heike C, Nitzke T, Vogler H, Hoschke B. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation. Urol Int. 2004; 72:103-111.
23. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol. 2000;163:73-78.
24. Lee CT, Dunn RL, Ingold C, Montie JE, Wood DP Jr. Early-stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion. Urology. 2007;69:1068-1072.
25. Larsson P, Wijkstrom H, Thorstenson A, et al. A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand J Urol Nephrol. 2003;37:195-201.
26. Smith Sehdev AE, Hutchins GM. Problems with proper completion and accuracy of the cause-of-death statement. Arch Intern Med. 2001;161:277-284.
27. Snyder C, Harlan L, Knopf K, Potosky A, Kaplan R. Patterns of care for the treatment of bladder cancer. J Urol. 2003;169:1697-1701.
28. Donat SM. Evaluation and follow-up strategies for superficial bladder cancer. Urol Clin North Am. 2003;30:765-776.